Exagen to Announce First Quarter 2022 Financial Results on May 11, 2022
SAN DIEGO, April 25, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended March 31, 2022, after the market close on Wednesday, May 11, 2022. Ron Rocca, Exagen’s President and Chief Executive Officer, Kamal Adawi, Chief Financial Officer, and Mark Hazeltine, Chief Operating Officer, will host a conference call to review the Company’s results at 4:30 PM ET (1:30 PM PT).
Interested parties may access the conference call by dialing (855) 238-9398 (U.S.) or (412) 317-5230 (international). Participants wishing to access the call via webcast should use the link posted on the Exagen investor relations website at investors.exagen.com.
A replay of the conference call will be available until Wednesday, May 18, 2022, at 11:59 PM ET (8:59 PM PT). Interested parties may access the replay of the conference call by dialing (844) 512-2921 (U.S.) or (412) 317-6671 (international) using passcode 10166625. Additionally, a recording of the webcast will be available using the link on the Exagen investor relations website approximately 30 minutes after the call concludes.
About Exagen Inc.
Exagen is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. Exagen has developed and is commercializing a portfolio of innovative testing products under its AVISE® brand, several of which are based on our proprietary Cell-Bound Complement Activation Products, or CB-CAPs, technology. Exagen’s goal is to enable providers to improve care for patients through the differential diagnosis, prognosis, and monitoring of complex autoimmune and autoimmune-related diseases, including rheumatoid arthritis and lupus.
Kamal Adawi, Chief Financial Officer
- Press release Biocartis Group NV: Biocartis Announces Presentation of Three Idylla™ Studies at 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID)
- Ramsay Sante : positive outcome of the recommended public offer to acquire GHP Specialty Care
- OnKure Therapeutics Expands Boulder Footprint with the Opening of a New Research Laboratory